medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2019, Number 1

<< Back Next >>

VacciMonitor 2019; 28 (1)

Local tolerance study of the VA-MENGOC-BC® antimeningococcal vaccine in Sprague Dawley rats. Evaluation at 24 and 36 months of shelf

Oliva-Hernández R, Fariñas-Medina M, Infante-Bourzac JF, Hernández-Salazar T, Núñez-Martínez D, Quintero-Pérez A, Campa-Huergo C, Sierra-González G

Language: Spanish
References: 25
Page: 9-18
PDF size: 373.09 Kb.


ABSTRACT

Meningococcal meningitis continues to be a health problem in different countries and different vaccines have been obtained for the prevention of this disease. VA-MENGOC-BC® vaccine has been effective and safe in the prevention of meningococcal meningitis against serogroups B and C. This has shown good stability over time without changing its quality as a product; It was stored on a shelf for 24 and 36 months at temperatures of 4 to 8 ºC. Their possible toxicological potential was evaluated through a local tolerance study in Sprague Dawley rats. Immunized animals were observed daily to evaluate local and systemic toxicity symptoms. Body weight, water and feed intake, thermometry, musculometry were performed and dermal irritability by the Draize method. Anatomopathological studies to observe possible adverse effects were made. No symptoms of toxicity or deaths were observed. No differences were found between the experimental groups in terms of body weight, water and food consumption, no fever or local irritability was evident. Anatomopathologically no lesions of diagnostic value were observed, at the site of inoculation, granulomatous processes of macrophagic type characteristic in vaccines containing aluminum hydroxide were observed. These results allowed us to conclude that the VA-MENGOC-BC® vaccine that remained on the shelf for 24 and 36 months did not show any local or systemic effects in rats.


REFERENCES

  1. World Health Organization. Epidemic meningitis control in countries of the African meningitis belt. The Weekly Epidemiological Record. 2018;93(14):173–84. Disponible en: http://www.who.int/wer.

  2. World Health Organization. [Homepage on the internet]. Geneva: Developing a new generation Rapid Diagnostic Tests for Meningitis; 2018. Disponible en: http://www.who.int/emergencies/ diseases/meningitis/en/.

  3. World Health Organization. [Homepage on the internet]. Geneva: Situation Update on Meningitis C Epidemic risk; 2017. Disponible en: http://www.who.int/mediacentre/infographic/meningitis/en/.

  4. World Health Organization. Guidelines on the evaluation of vaccine adjuvants and adjuvanted vaccine, Technical Report Series No 987, Annex 2. Geneva: WHO; 2013. Disponible en: http://www.who. int/biologicals/vaccines/nonclinial_evaluation_of_vaccines/en/.

  5. World Health Organization. Guidelines on nonclinical evaluation of vaccine. Technical Report Series, No. 927. Geneva: WHO; 2005 Disponible en: http://www.who.int/biologicals/vaccines/ nonclinial_evaluation_of_vaccines/en/.

  6. Draize JH, Woodard G, Calvery HO. Methods for the Study of Irritation and Toxicity of Substances Applied Topically to the Skin and Mucous Membranes. Journal of Pharmacology and Experimental Therapeutics 1944; 3(82):377-90.

  7. Verdier F. Non-clinical vaccine safety assessment. Toxicology 2002;134(1):37-43.

  8. Organization for Economic Cooperation and Development. Guideline for the Testing of Chemicals No 404. Paris: OECD; 2004. Disponible en: http://www.oecd.org/env/testguidelines .

  9. The National Academies Press. Guide for the care and use of laboratory animals. Eighth Edition. Washington: NAP; 2010. Disponible en: https://www.nap.edu/download/12910.

  10. American Veterinary Medical Association. Guidelines on euthanasia. Schaumburg IL: AVMA; 2013. Disponible en: https:// www.avma.org/KB/Policies/Pages/Euthanasia-Guidelines.aspx.

  11. Morton DB. Humane endpoints in animal experimentation for biomedical research: ethical, legal and practical aspect. Laboratory animals 2005;8:5-12.

  12. R Development Core Team. R: A language and environment for statistical computing. Vienna: GBIF; 2014. Disponible en: http:// www.R-project.org/.

  13. Núñez JF, Herrera L, Infante JF, González P, Pérez V, Argamasilla M, et al: Estudio de toxicidad por dosis única y tolerancia local de una vacuna antimeningocócica tipo B en ratas Sprague Dawley. Vaccimonitor 2006;15(2) 9-14.

  14. Infante Bourzac JF. Estudio de inocuidad e inmunogenicidad protectogénica de la vacuna antimeningocócica VA-MENGOCBC en modelos murinos. [Tesis Doctoral]. La Habana: Universidad Agraria de la Habana; 2000.

  15. Fariñas M, Oliva R, Infante JF, Valdez Y, Nuñez D, Valmaceda T, et al. Ensayo piloto de inmunogenicidad y toxicidad preclínica de la vacuna Salmonella typhi conjugada en ratas Sprague Dawley. Retel. 2014;44:17-34. Disponible en: http://www.sertox.com.ar/ modules.php?name=Content&pa=showpage&pid=936.

  16. López Y, Pastor M, Infante JF, Díaz D, Oliva R, Fernández S, et al. Repeated dose toxicity study of Vibrio cholerae-loaded gastroresistant microparticles. J Microencapsul 2014;31:86-92.

  17. Fariñas M, Arencibia DF, Días D, Infante JF, Valdés Y, Hernández T, et al. Estudio de Toxicidad por Dosis Única de la Vacuna Antimeningocóccica ACW135 en Ratas Sprague Dawley. Retel. 2011;35:23-42. Disponible en: https://www.sertox.com.ar/ modules.php?name=Content&pa=showpage&pid=775.

  18. Charles River Laboratories. [Homepage on the internet]. Wilmington MA: Charles River Labs-Research Models, Sprague Dawley Rat Informational Resources; 2018. Disponible en: https:// www.criver.com/products-services/find-model/sas-spraguedawley- rat?region=3616.

  19. Taconic Technical Library. [Homepage on the internet]. Cambridge: Taconic Sprague Dawley, Growth and Phenotyping Data; 2018. Disponible en: http://www.taconic.com/rat-model/ sprague-dawley.

  20. Canadian Council on Animal Care. Guide to the care and use of experimental animals: Ottawa: CCAC; 1984.

  21. Ochoa RF, Baró IM, Menéndez J, Triana T, Mirabal M, Armesto M, et al. Reactogenicidad e inmunogenicidad de una nueva vacuna de toxoide tetánico y diftérico con concentración reducida en adolescentes cubanos. VacciMonitor 2006;15(2):13-7.

  22. García HM, Thompson R, Valera R, Fando R, Fumane J, Mirabal M, et al. A single dose of live-attenuated 638 Vibrio cholerae oral vaccine is safe and immunogenic in adult volunteers in Mozambique. VacciMonitor 2011;20(3):1-8.

  23. Hexagon. Standard Gage. Precision Measuring Instruments. Estocolmo: Hexagon Metrology; 2018. Disponible en: https:// www.merici-pristroje.cz/files/ckeditor//5_Produkty/Standard_ gage/Standard_Gage.pdf.

  24. Liguori GR, Jeronimus BF, de Aquinas Liguori TT, Moreira LFP, Harmsen MC. Ethical Issues in the Use of Animal Models for Tissue Engineering: Reflections on Legal Aspects, Moral Theory, Three Rs Strategies, and Harm–Benefit Analysis. Tissue Engineering Part C: Methods. 2017;23(12):850-62.

  25. Organization for Economic Cooperation and Development. Test No 439, In Vitro Skin Irritation, Reconstructed Human Epidermis Test Method. Paris: OECD; 2015 Disponible en: http://dx.doi. org/10.1787/9789264242845-en.




2020     |     www.medigraphic.com